Lantheus Medical announced Monday that the international radiopharmaceutical company has entered an agreement with Wisconsin-based Shine Medical Technologies for supply of molybdenum-99 (Mo-99).

A spike in regulatory requirements has been reported by Regulatory Focus according to data released by George Mason University's Mercatus Center for market research in Arlington, Va. According to the numbers, FDA requirements picked up 15 percent from the year 2000 until 2012.

Here is more incentive to bring investigative Alzheimer’s treatments to maturity—approximately a quarter of caregivers with a family member diagnosed with Alzheimer’s disease or another dementia end up paying out $4,000 in disease-related costs on a monthly basis, according to a survey released today from AgingCare.com

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) today released a statement from Bayer HealthCare dated Oct. 21 providing more information to healthcare professionals about the ongoing shortfall in Ra-223 dichloride (Xofigo) prescribed for castration-resistant prostate cancer with metastases to the bone.

“The cost of global cybercrimes now exceeds the revenue from the global drug trade,” said David Anderson of consulting firm CliftonLarsenAllen at the start of his presentation to RBMA members on information security at the RBMA Fall Educational Conference in Seattle. “Every second of the day, people are out there looking for the weak link." 

Three biomedical companies from across the globe are banding together with research institutions to develop knowledge about a “super-family” of protein receptors called G-protein coupled receptors (GPCRs). Images of these biomarkers could open the door to a new era of pharmaceuticals.

Over the next five years, the National Institutes of Health (NIH) will be rolling out $30 million in funding for research gleaning new information and treatments for frontotemporal degeneration, the culprit in many cases of early onset dementia, the Association for Frontotemporal Degeneration announced this week.

Intraoperative cytoscopic imaging being developed at Stanford University School of Medicine uses antibodies and fluorescence to home in on a protein target called CD47 to improve surgical accuracy, the institution announced Wednesday.